Antineoplastic agent: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
imported>Robert Badgett
Line 80: Line 80:
ATC/DDD group [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01XC L01XC]. Examples include:
ATC/DDD group [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01XC L01XC]. Examples include:
;[http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_005219 EGRF]  
;[http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_005219 EGRF]  
* [Panitumumab] is an "antibody that blocks receptors for epidermal growth factor; approved for advanced [[colorectal cancer|colon cancer]]".<ref>{{MeSH|Panitumumab [Substance Name]}}</ref>
* [[Panitumumab]] is an "antibody that blocks receptors for epidermal growth factor; approved for advanced [[colorectal cancer|colon cancer]]".<ref>{{MeSH|Panitumumab [Substance Name]}}</ref>


;[http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_002345 EpCAM]
;[http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_002345 EpCAM]
* [Edrecolomab] ("anticolorectal carcinoma antibody for treatment of advanced [[colorectal cancer|colorectal carcinoma]]".<ref>{{MeSH|edrecolomab [Substance Name]}}</ref>
* [[Edrecolomab]] is a "anticolorectal carcinoma antibody for treatment of advanced [[colorectal cancer|colorectal carcinoma]]".<ref>{{MeSH|edrecolomab [Substance Name]}}</ref>


;[http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=BAE15960 ERBB2]
;[http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=BAE15960 ERBB2]
* [Trastuzumab] is a "HER2 antibody that lengthens remission time in metastatic [[breast cancer]]."<ref>{{MeSH|Trastuzumab [Substance Name]}}</ref>
* [[Trastuzumab]] is a "HER2 antibody that lengthens remission time in metastatic [[breast cancer]]."<ref>{{MeSH|Trastuzumab [Substance Name]}}</ref>


;[http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NM_000732 CD3] and [http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_002345 EpCAM]
;[http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NM_000732 CD3] and [http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_002345 EpCAM]
* [Catumaxomab] is a "".<ref>{{MeSH|Catumaxomab [Substance Name]}}</ref>
* [[Catumaxomab]]. "Extracorporeal PBMNC coating with catumaxomab may be an option to control intravascular cytokine release induced by therapeutic antibodies".<ref>{{MeSH|Catumaxomab [Substance Name]}}</ref>


;[http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_690605 MS4A1] (CD20 antigen)
;[http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_690605 MS4A1] (CD20 antigen)
* [Rituximab] is a "genetically engineered anti-CD20 antibody for the treatment of B-cell lymphoma".<ref>{{MeSH|Rituximab [Substance Name]}}</ref>
* [[Rituximab]] is a "genetically engineered anti-CD20 antibody for the treatment of B-cell lymphoma".<ref>{{MeSH|Rituximab [Substance Name]}}</ref>


;[http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=SIGLEC3 SIGLEC3] (CD33)
;[http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=SIGLEC3 SIGLEC3] (CD33)
* [Gemtuzumab] is an "anti-CD33 antibody calicheamicin conjugate".<ref>{{MeSH|Gemtuzumab [Substance Name]}}</ref>
* [[Gemtuzumab]] is an "anti-CD33 antibody calicheamicin conjugate".<ref>{{MeSH|Gemtuzumab [Substance Name]}}</ref>


;[http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=CAI15846 CD52 molecule]
;[http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=CAI15846 CD52 molecule]
* [Alemtuzumab] is a "a therapeutic antibody directed against the CDw52 antigen expressed by the lymphocytes and has proven lytic abilities both in vitro and in vivo; has been sequenced".<ref>{{MeSH|Alemtuzumab [Substance Name]}}</ref>
* [[Alemtuzumab]] is a "a therapeutic antibody directed against the CDw52 antigen expressed by the lymphocytes and has proven lytic abilities both in vitro and in vivo; has been sequenced".<ref>{{MeSH|Alemtuzumab [Substance Name]}}</ref>


;[http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_001020537 VEGFA]
;[http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_001020537 VEGFA]
* [Bevacizumab] is an "anti-VEGF monoclonal antibody consisting of humanized murine antibody with antigen-binding, complementary-determining regions from murine VEGF".<ref>{{MeSH|Bevacizumab [Substance Name]}}</ref>
* [[Bevacizumab]] is an "anti-VEGF monoclonal antibody consisting of humanized murine antibody with antigen-binding, complementary-determining regions from murine VEGF".<ref>{{MeSH|Bevacizumab [Substance Name]}}</ref>


==== Sensitizers used in photodynamic/radiation therapy====
==== Sensitizers used in photodynamic/radiation therapy====

Revision as of 21:11, 4 February 2009

This article is developing and not approved.
 Main Article
 Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
https://en.citizendium.org/wiki/index.php?title=Antineoplastic_agent&printable=yes
This editable Main Article is under development and subject to a disclaimer.

In medicine, antineoplastic agents are "substances that inhibit or prevent the proliferation of neoplasms".[1] Generally, antineoplastic agents are for treating malignant neoplasms such as cancers and sarcomas.

Classification

This classification is based on World Health Organization's Collaborating Centre for Drug Statistics Methodology.[2]

Alkylating agents

ATC/DDD group L01A. Alkylating antineoplastic agents are a "class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood."[3]

Nitrogen mustard analogues

ATC/DDD group L01AA.

Alkyl sulfonates

ATC/DDD group L01AB.

Ethylene imines

ATC/DDD group L01AC.

Nitrosoureas

ATC/DDD group L01AD.

Epoxides

ATC/DDD group L01AG.

Other alkylating agents

ATC/DDD group L01AX.

Antimetabolites

ATC/DDD group L01B. Antineoplastic antimetabolites are "antimetabolites that are useful in cancer chemotherapy."[4]

Folic acid analogues

ATC/DDD group L01BA.

Purine analogues

ATC/DDD group L01BB.

Pyrimidine analogues

ATC/DDD group L01BC.

Plant alkaloids and other natural products

ATC/DDD group L01C.

Vinca alkaloids and analogues

ATC/DDD group L01CA.

Podophyllotoxin derivatives

ATC/DDD group L01CB.

Colchicine derivatives

ATC/DDD group L01CC.

Taxanes

ATC/DDD group L01CD.

Other plant alkaloids and natural products

ATC/DDD group L01CX.

Cytotoxic antibiotics and related substances

ATC/DDD group L01D.

Actinomycines

ATC/DDD group L01DA.

Anthracyclines and related substances

ATC/DDD group L01DB.

Other cytotoxic antibiotics

ATC/DDD group L01DC.

Other antineoplastic agents

ATC/DDD group L01X.

Platinum compounds

ATC/DDD group L01XA.

Methylhydrazines

ATC/DDD group L01XB.

Monoclonal antibodies

ATC/DDD group L01XC. Examples include:

EGRF
EpCAM
ERBB2
CD3 and EpCAM
  • Catumaxomab. "Extracorporeal PBMNC coating with catumaxomab may be an option to control intravascular cytokine release induced by therapeutic antibodies".[8]
MS4A1 (CD20 antigen)
  • Rituximab is a "genetically engineered anti-CD20 antibody for the treatment of B-cell lymphoma".[9]
SIGLEC3 (CD33)
CD52 molecule
  • Alemtuzumab is a "a therapeutic antibody directed against the CDw52 antigen expressed by the lymphocytes and has proven lytic abilities both in vitro and in vivo; has been sequenced".[11]
VEGFA
  • Bevacizumab is an "anti-VEGF monoclonal antibody consisting of humanized murine antibody with antigen-binding, complementary-determining regions from murine VEGF".[12]

Sensitizers used in photodynamic/radiation therapy

ATC/DDD group L01XD.

Protein kinase inhibitors

ATC/DDD group L01XE. Examples include matinib, gefitinib, erlotinib, sunitinib, sorafenib, dasatinib, lapatinib, nilotinib, and temsirolimus.

References

  1. ↑ Anonymous (2024), Antineoplastic agent (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. ↑ Anonymous. WHO Collaborating Centre for Drug Statistics Methodology. World Health Organization. Retrieved on 2009-02-04.
  3. ↑ Anonymous (2024), Antineoplastic Agents, Alkylating (English). Medical Subject Headings. U.S. National Library of Medicine.
  4. ↑ Anonymous (2024), Antineoplastic Agents, Alkylating (English). Medical Subject Headings. U.S. National Library of Medicine.
  5. ↑ Anonymous (2024), Panitumumab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
  6. ↑ Anonymous (2024), edrecolomab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
  7. ↑ Anonymous (2024), Trastuzumab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
  8. ↑ Anonymous (2024), Catumaxomab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
  9. ↑ Anonymous (2024), Rituximab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
  10. ↑ Anonymous (2024), Gemtuzumab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
  11. ↑ Anonymous (2024), Alemtuzumab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
  12. ↑ Anonymous (2024), Bevacizumab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
Retrieved from "https://citizendium.org/wiki/index.php?title=Antineoplastic_agent&oldid=578511"